XP13512 [(±)-1-([(α-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters

Journal of Pharmacology and Experimental Therapeutics

Volumn 311, Issue 1, 2004, Pages 315-323

  Cundy, Kenneth C ^a   Branch, Russell ^a   Chernov Rogan, Tania ^a   Dias, Tracy ^a   Estrada, Toño ^a   Hold, Karin ^a   Koller, Kerry ^a   Liu, Xiaoli ^a   Mann, Adam ^a   Panuwat, Matt ^a   Raillard, Stephen P ^a   Upadhyay, Shubhra ^a   Wu, Quincey Q ^a   Xiang, Jia Ning ^a   Yan, Hui ^a   Zerangue, Noa ^a   Zhou, Cindy X ^a   Barrett, Ronald W ^a   Gallop, Mark A ^a  

^a XenoPort Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [[(ALPHA ISOBUTANOYLOXYETHOXY)CARBONYL]AMINOMETHYL] 1 CYCLOHEXANE ACETIC ACID; ACETIC ACID DERIVATIVE; CARBON 14; CYTOCHROME P450; GABAPENTIN; ISOPROTEIN; LACTIC ACID; PRODRUG; UNCLASSIFIED DRUG; XP 13512; 1 (((ALPHA ISOBUTANOYLOXYETHOXY)CARBONYL)AMINOMETHYL) 1 CYCLOHEXANEACETIC ACID; 1-(((ALPHA-ISOBUTANOYLOXYETHOXY)CARBONYL)AMINOMETHYL)-1-CYCLOHEXANEACETIC ACID; 4 AMINOBUTYRIC ACID; AMINE; AMINO ACID TRANSPORTER; BIOTIN TRANSPORTER; CARBAMIC ACID DERIVATIVE; COTRANSPORTER; CYCLOHEXANECARBOXYLIC ACID DERIVATIVE; DRUG DERIVATIVE; MONOCARBOXYLATE TRANSPORTER;

ANIMAL CELL; ARTICLE; CELL STRAIN CACO 2; CHO CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOG; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TRANSPORT; DRUG UPTAKE; EMBRYO; ENZYME ACTIVITY; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; IN VITRO STUDY; INTESTINE ABSORPTION; LIQUID CHROMATOGRAPHY; LIVER; MONKEY; NONHUMAN; PH MEASUREMENT; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; ANIMAL; ARTIFICIAL MEMBRANE; FEMALE; HAMSTER; INTESTINE; METABOLISM; PROTEIN BINDING; RAT; SYNTHESIS; TRANSPORT AT THE CELLULAR LEVEL;

AMINES; ANIMALS; BIOLOGICAL TRANSPORT; CACO-2 CELLS; CARBAMATES; CHO CELLS; CRICETINAE; CYCLOHEXANECARBOXYLIC ACIDS; CYTOCHROME P-450 ENZYME SYSTEM; DOGS; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; INTESTINES; LARGE NEUTRAL AMINO ACID-TRANSPORTER 1; MEMBRANES, ARTIFICIAL; MONOCARBOXYLIC ACID TRANSPORTERS; PRODRUGS; PROTEIN BINDING; RATS; SYMPORTERS;

EID: 4644328982     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.104.067934     Document Type: Article

References (41)

1. Alexander J, Cargill R, Michelson SR, and Schwam H (1988) (Acyloxy)alkyl carbamates as novel bioreversible prodrugs for amines: increased permeation through biological membranes. J Med Chem 31:318-322.
2. Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes M, LaMoreaux L, and Garofalo E (1998) Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. J Am Med Assoc 280:1831-1836.
3. Barth CA, Rigg M, and Hagenmeister H (1986) Biotin absorption from the hind-gut of the pig. J Anim Physiol Anim Nutr 55:128-134.
4. Berry DJ, Beran RG, Plunkett MJ, Clarke LA, and Hung WT (2003) The absorption of gabapentin following high dose escalation. Seizure 12:28-36.
5. Boyd RA, Turck D, Abel RB, Sedman AJ, and Bockbrader HN (1999) Effects of age and gender on single-dose pharmacokinetics of gabapentin. Epilepsia 40:474-479.
6. Campbell CJ and Langley C (1985) Measurement of rat-intestinal cefuroxime axetil esterase activity: comparison of an HPLC and coupled-enzyme assay. Xenobiotica 15:1011-1019.
7. Cundy KC, Annamalai T, Bu L, De Vera J, Estrela J, Luo W, Shirsat P, Torneros A, Yao F, Zou J, et al. (2004) XP13512 [(±)-1-([(α- isobutanoyloxyethoxy)carbonyl]aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys. J Pharmacol Exp Ther 311:324-333.
8. Duelli R, Enerson BE, Gerhart DZ, and Drewes LR (2000) Expression of large amino acid transporter LAT1 in rat brain endothelium. J Cereb Blood Flow Metab 20:1557-1562.
9. Enerson BE and Drewes LR (2003) Molecular features, regulation and function of monocarboxylate transporters: implications for drug delivery. J Pharm Sci 92: 1531-1544.
10. Garcia-Borreguero D, Larrosa O, de la Llave Y, Verger K, Masramon X, and Hernandez G (2002) Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. Neurology 59:1573-1579.
11. Gidal BE, DeCerce J, Bockbrader HN, Gonzalez J, Kruger S, Pitterle ME, Rutecki P, and Ramsay RE (1998) Gabapentin bioavailability: effect of dose and frequency of administration in adult patients with epilepsy. Epilepsy Res 31:91-99.
12. Gidal BE, Radulovic LL, Kruger S, Rutecki P, Pitterle M, and Bockbrader HN (2000) Inter- and intra-subject variability in gabapentin absorption and absolute bioavailability. Epilepsy Res 40:123-127.
13. Gleiter CH and Morike KE (2002) Clinical pharmacokinetics of candesartan. Clin Pharmacokinet 41:7-17.
14. Guttuso T Jr, Kurlan R, McDermott MP, and Kieburtz K (2003) Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol 101:337-345.
15. Halestrap AP and Price NT (1999) The proton-linked monocarboxylate transporter (MCT) familiy: structure, function and regulation. Biochem J 343:281-299.
16. Kriel RL, Birnbaum AK, Cloyd JC, Ricker BJ, Jones Saete C, and Caruso KJ (1997) Failure of absorption of gabapentin after rectal administration. Epilepsia 38:1242-1244.
17. Lagrèze WA, Muller-Velten R, and Feuerstein TJ (2001) The neuroprotective properties of gabapentin-lactam. Graefes Arch Clin Exp Ophthalmol 239:845-849.
18. Matsuo H, Tsukada S, Nakata T, Chairoungdua A, Kim DK, Cha SH, Inatomi J, Yorifuji H, Fukuda J, Endou H, et al. (2000) Expression of a system L neutral amino acid transporter at the blood-brain barrier. Neuroreport 11:3507-3511.
19. McLean MJ (1999) Gabapentin in the management of convulsive disorders. Epilepsia 40 (Suppl 6):S39-S50.
20. McLean MJ (1995) Gabapentin. Epilepsia 36 (Suppl 2):S73-S86.
21. Pollack MH, Matthews J, and Scott EL (1998) Gabapentin as a potential treatment for anxiety disorders. Am J Psychiatry 155:992-993.
22. Potschka H, Feuerstein TJ, and Loscher W (2000) Gabapentin-lactam, a close analogue of the anticonvulsant gabapentin, exerts convulsant activity in amygdala kindled rats. Naunyn Schmiedebergs Arch Pharmacol 361:200-205.
23. +-dependent multivitamin transporter. Arch Biochem Biophys 366:95-106.
24. Prasad PD, Wang H, Huang W, Kekuda R, Rajan DP, Leibach FH, and Ganapathy V (1999b) Human LAT1, a subunit of system L amino acid transporter: molecular cloning and transport function. Biochem Biophys Res Commun 16:283-288.
25. Radulovic L, Turck D, Von Hodenberg A, Vollmer K, McNally W, Dehart P, Hanson B, Bockbrader H, and Chang T (1995) Disposition of gabapentin (Neurontin) in mice, rats, dogs and monkeys. Drug Metab Dispos 23:441-448.
26. Reynolds RC (1998) Metabolism and pharmacokinetics of sucrose acetate isobutyrate (SAIB) and sucrose octa-isobutyrate (SOIB) in rats, dogs, monkeys or humans: a review. Food Chem Toxicol 36:95-99.
27. Rice AS and Maton S; Postherpetic Neuralgia Study Group (2001) Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain 94:215-224.
28. Richter A, Anton SE, Koch P, and Dennett SL (2003) The impact of reducing dose frequency on health outcomes. Clin Ther 25:2307-2335.
29. Rowbotham M, Harden N, Stacey B, Bernstein P, and Magnus-Miller L (1998) Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. J Am Med Assoc 280:1837-1842.
30. Said HM, Ortiz A, McCloud E, Dyer D, Moyer MP, and Rubin S (1998) Biotin uptake by human colonic epithelial NCM460 cells: a carrier-mediated process shared with pantothenic acid. Am J Physiol 275:C1365-C1371.
31. Sekine T, Kusuhara H, Utsunomiya-Tate N, Tsuda M, Sugiyama Y, Kanai Y, and Endou H (1998) Molecular cloning and characterization of high-affinity carnitine transporter from rat intestine. Biochem Biophys Res Commun 251:586-591.
32. Slitt AL, Cherrington NJ, Hartley DP, Leazer TM, and Klaassen CD (2002) Tissue distribution and renal developmental changes in rat organic cation transporter mRNA levels. Drug Metab Dispos 30:212-219.
33. Sorrell MF, Frank O, Thomson AD, Aquino A, and Baker H (1971) Absorption of vitamins from the large intestine. Nutr Res Int 3:143-148.
34. Stein J, Zores M, and Schroder O (2000) Short-chain fatty acid (SCFA) uptake into Caco-2 cells by a pH-dependent and carrier mediated transport mechanism. Eur J Nutr 39:121-125.
35. Stewart BH, Chan OH, Lu RH, Reyner EL, Schmid HL, Hamilton HW, Steinbaugh BA, and Taylor MD (1995) Comparison of intestinal permeabilities determined in multiple in vitro and in situ models: relationship to absorption in humans. Pharm Res (NY) 12:693-699.
36. Stewart BH, Kugler AR, Thompson PR, and Bockbrader HN (1993) A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharm Res (NY) 10:276-281.
37. Sugano K, Hamada H, Machida M, Ushio H, Saitoh K, and Terada K (2001) Optimized conditions of bio-mimetic artificial membrane permeation assay. Int J Pharm 228:181-188.
38. Tamai I, Ohashi R, Nezu J, Yabuuchi H, Oku A, Shimane M, Sai Y, and Tsuji A (1998) Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2. J Biol Chem 273:20378-20382.
39. Tosco M, Orsenigo MN, Gastaldi G, and Faelli A (2000) An endogenous monocarboxylate transport in Xenopus laeuis oocytes. Am J Physiol Regul Integr Comp Physiol 278:R1190-5.
40. Uchino H, Kanai Y, Kim do K, Wempe MF, Chairoungdua A, Morimoto E, Anders MW, and Endou H (2002) Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition. Mol Pharmacol 61:729-737.
41. +-dependent multivitamin transporter: cloning, functional expression, gene structure and chromosomal localization. J Biol Chem 274:14875-14883.